September 17th 2021EP. 1: An Overview of the FIGARO-DKD Trial Design
An overview of the FIGARO-DKD trial, which evaluated cardiovascular and renal outcomes in patients with type 2 diabetes and CKD treated with finerenone.
September 17th 2021EP. 2: Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD
Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points.
September 24th 2021EP. 3: An Overview of the FIDELITY Pooled Analysis Design
An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.
September 24th 2021EP. 4: Results From the FIDELITY Pooled Analysis
A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD.
October 1st 2021EP. 5: Practical Implications of the FIDELITY Pooled Analysis
Rajiv Agarwal, MD, MS, considers the practical implications of the FIDELITY pooled analysis and how it may impact clinical practice.
October 1st 2021EP. 6: Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors
Considerations for the benefit shown in combining finerenone with SGLT2 inhibitors in patients with type 2 diabetes and CKD.
October 8th 2021EP. 7: Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF
An overview of and results from the EMPEROR-Preserved trial, which tested the effects of empagliflozin in patients with HFpEF.
October 8th 2021EP. 8: Results From the EMPEROR-Pooled Analysis
Rajiv Agarwal, MD, MS, reflects on pooled data from the EMPEROR-Reduced and EMPEROR-Preserved trials.
October 15th 2021EP. 9: Unmet Needs in the Management of Heart Failure
Insight on the unmet needs in management of heart failure, specifically regarding access to therapeutic agents that can alter the course of disease.
October 15th 2021EP. 10: Results From the STEP Trial in China
A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.
